Abstract: The inventors have discovered that a CK?8-1 truncation variant, CK?8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK?8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK?8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK?8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided.

Abstract: Antibodies that bind to CCX-CKR2 and methods of their use are provided.

Abstract: The present invention provides method and compositions for modulating angiogenesis.

Abstract: Antibodies that bind to CCX-CKR2 and methods of their use are provided.

Abstract: This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).

Abstract: Antibodies that bind to CCX-CKR2 and methods of their use are provided.

Abstract: An innovative sleeping suit for infants, configured to provide warmth, a contained environment, and positive proprioceptive input, and thereby reduce neurological reflexive twitching or habitual waking patterns prevalent when infants are placed on their backs for sleeping and are not swaddled. The weighting in the suit is believed to reduce the neurological reflexive twitching and provides a swaddling effect to infants helping them to fall asleep and remain sleeping when on their backs. At least a portion of an anterior portion of the suit includes the weighting. The weighting may be accomplished by varying the thickness of the materials and/or quantity of layers of materials used on the anterior portion of the suit. The weighting may be distributed uniformly throughout the suit, the anterior portion of the suit, or can be strategically placed at proprioceptive target points along the anterior portion of the suit.

Abstract: The inventors have discovered that a CK?8-1 truncation variant, CK?8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK?8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK?8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK?8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided.

Abstract: The present invention provides method and compositions for modulating angiogenesis.

Abstract: Ligands of CCX—CKR2 and the biological role of CCX—CKR2 in cancer is described.

Abstract: This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

Abstract: This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).

Abstract: The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.

Abstract: The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.

Abstract: A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.

Abstract: A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.

Abstract: A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.